P05.92 Brain invasion in meningiomas previously classified as WHO grade I has limited impact on outcome

Por Biczok, A, Suchorska, B, Egensperger, R, Tonn, J, Schichor, C
Publicado no Neuro Oncol (2018)

Acoustic neuroma surgery as an interdisciplinary approach: a neurosurgical series of 508 patients

Por Tonn, J., Schlake, H., Goldbrunner, R., Milewski, C., Helms, J., Roosen, K.
Publicado em 2000

O5.06 CYSTIC CRANIOPHARYNGIOMAS: MICROSURGICAL OR STEREOTACTIC TREATMENT?

Por Rachinger, W., Kunz, M., Thon, N., Tonn, J.C., Kreth, F.W.
Publicado em 2014

P07.16 Prognostic value of contrast enhancement and histopathological grading in diffuse gliomas depends on IDH1/2 mutation

Por Suchorska, B., Biczok, A., Lenski, M., Albert, N. L., Schüller, U., Tonn, J.
Publicado no Neuro Oncol (2016)

Visual field defect in association with chiasmal migration of intraocular silicone oil

Por Eckle, D, Kampik, A, Hintschich, C, Haritoglou, C, Tonn, J-C, Uhl, E, Lienemann, A
Publicado em 2005

Cervicothoracic Intradural Arachnoid Cyst Misdiagnosed as Motor Neuron Disease

Por Sämann, P. G., Himmerich, H., Merl, T., Erös, C., Müller, M. B., Tonn, J. C., Buchwald, B.
Publicado em 2010

O7.09 [(68)GA]-DOTATATE-PET IMAGING PREDICTS SOMATOSTATIN RECEPTOR II EXPRESSION IN MENINGIOMAS

Por Rachinger, W., Stöcklein, V., Haug, A.R., Schüller, U., Schichor, C., Thon, N., Tonn, J.C.
Publicado em 2014

P04.27 Texture feature analysis to predict overall survival in recurrent glioblastoma treated in the DIRECTOR trial

Por Vils, A., Wirsching, H., Nesteruk, M., Tanadini-Lang, S., Reifenberger, G., Tonn, J., Guckenberger, M., Wick, W., Andratschke, N., Weller, M.
Publicado no Neuro Oncol (2017)

P08.30 Extended temozolomide for newly diagnosed glioblastoma: an analysis of the German Glioma Network

Por Gramatzki, D., Kickingereder, P., Hentschel, B., Schramm, J., Tonn, J. C., Schackert, G., Reifenberger, G., Löffler, M., Bendszus, M., Weller, M.
Publicado no Neuro Oncol (2016)

P01.131 Non-invasive detection ofIDH-wildtype genotype in gliomas using dynamic18F-FET-PET

Por Suchorska, B, Vettermann, F, Unterrainer, M, Nelwan, D, Forbrig, R, Dorostkar, M, Kreth, F W, Bartenstein, P, Tonn, J C, Albert, N
Publicado no Neuro Oncol (2018)

Expression of BARHL1 in medulloblastoma is associated with prolonged survival in mice and humans

Por Pöschl, J, Lorenz, A, Hartmann, W, von Bueren, AO, Kool, M, Li, S, Peraud, A, Tonn, J-C, Herms, J, Xiang, M, Rutkowski, S, Kretzschmar, HA, Schüller, U
Publicado no Oncogene (2011)

OS2.1 Objective responses to chemotherapy in recurrent glioma do not predict better survival: A prospective analysis from the German Glioma Network

Por Bähr, O, Hentschel, B, Hattingen, E, Reusche, M, Tatagiba, M, Tonn, J, Schnell, O, Schackert, G, Westphal, M, Herrlinger, U, Pietsch, T, Reifenberger, G, Weller, M, Löffler, M, Steinbach, J P
Publicado no Neuro Oncol (2018)

Hot spots in dynamic(18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas

Por Kunz, M., Thon, N., Eigenbrod, S., Hartmann, C., Egensperger, R., Herms, J., Geisler, J., la Fougere, C., Lutz, J., Linn, J., Kreth, S., von Deimling, A., Tonn, J. C., Kretzschmar, H. A., Pöpperl, G., Kreth, F. W.
Publicado em 2011

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

Por Reardon, D A, Dresemann, G, Taillibert, S, Campone, M, van den Bent, M, Clement, P, Blomquist, E, Gordower, L, Schultz, H, Raizer, J, Hau, P, Easaw, J, Gil, M, Tonn, J, Gijtenbeek, A, Schlegel, U, Bergstrom, P, Green, S, Weir, A, Nikolova, Z
Publicado em 2009